Therapeutic antibody engineering: current and future advances driving the strongest growth area in the pharmaceutical industry
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge, UK
Woodhead Publishing
© 2013
|
| Schlagworte: | |
| Online-Zugang: | FAW01 URL des Erstveröffentlichers |
| Beschreibung: | Includes bibliographical references and index The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. Goes beyond the standard engineering issues covered by most books and delves into structure-function relationshipsIntegration of knowledge across all areas of antibody engineering, development, and marketingDiscusses how current and future genetic engineering of cell lines will pave the way for much higher productivity |
| Beschreibung: | xlvi, 650 pages |
| ISBN: | 1907568379 9781907568374 9781306189385 1306189381 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044383302 | ||
| 003 | DE-604 | ||
| 005 | 20190618 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170630s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 1907568379 |9 1-907568-37-9 | ||
| 020 | |a 9781907568374 |9 978-1-907568-37-4 | ||
| 020 | |a 9781306189385 |9 978-1-306-18938-5 | ||
| 020 | |a 1306189381 |9 1-306-18938-1 | ||
| 035 | |a (ZDB-33-ESD)ocn870891982 | ||
| 035 | |a (OCoLC)870891982 | ||
| 035 | |a (DE-599)BVBBV044383302 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 | ||
| 082 | 0 | |a 615.37 |2 23 | |
| 100 | 1 | |a Strohl, William R. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Therapeutic antibody engineering |b current and future advances driving the strongest growth area in the pharmaceutical industry |c William R. Strohl and Lila M. Strohl |
| 264 | 1 | |a Cambridge, UK |b Woodhead Publishing |c © 2013 | |
| 300 | |a xlvi, 650 pages | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. Goes beyond the standard engineering issues covered by most books and delves into structure-function relationshipsIntegration of knowledge across all areas of antibody engineering, development, and marketingDiscusses how current and future genetic engineering of cell lines will pave the way for much higher productivity | ||
| 610 | 2 | 7 | |a Antikörper |0 (DE-588)10319455-1 |2 gnd |9 rswk-swf |
| 650 | 4 | |a Antibodies, Monoclonal / therapeutic use | |
| 650 | 4 | |a Antibodies, Monoclonal / diagnostic use | |
| 650 | 7 | |a Immunotechnology |2 fast | |
| 650 | 7 | |a Monoclonal antibodies / Therapeutic use |2 fast | |
| 650 | 4 | |a Monoclonal antibodies |x Therapeutic use | |
| 650 | 4 | |a Immunotechnology | |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Antikörper |0 (DE-588)10319455-1 |D b |
| 689 | 0 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Strohl, Lila M. |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/book/9781907568374 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-33-ESD |a ZDB-33-EBS | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029785523 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u http://www.sciencedirect.com/science/book/9781907568374 |l FAW01 |p ZDB-33-ESD |q FAW_PDA_ESD |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804177648361930752 |
|---|---|
| any_adam_object | |
| author | Strohl, William R. |
| author_facet | Strohl, William R. |
| author_role | aut |
| author_sort | Strohl, William R. |
| author_variant | w r s wr wrs |
| building | Verbundindex |
| bvnumber | BV044383302 |
| collection | ZDB-33-ESD ZDB-33-EBS |
| ctrlnum | (ZDB-33-ESD)ocn870891982 (OCoLC)870891982 (DE-599)BVBBV044383302 |
| dewey-full | 615.37 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.37 |
| dewey-search | 615.37 |
| dewey-sort | 3615.37 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03684nmm a2200553zc 4500</leader><controlfield tag="001">BV044383302</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20190618 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170630s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1907568379</subfield><subfield code="9">1-907568-37-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781907568374</subfield><subfield code="9">978-1-907568-37-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781306189385</subfield><subfield code="9">978-1-306-18938-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1306189381</subfield><subfield code="9">1-306-18938-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-33-ESD)ocn870891982</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)870891982</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044383302</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.37</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Strohl, William R.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic antibody engineering</subfield><subfield code="b">current and future advances driving the strongest growth area in the pharmaceutical industry</subfield><subfield code="c">William R. Strohl and Lila M. Strohl</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, UK</subfield><subfield code="b">Woodhead Publishing</subfield><subfield code="c">© 2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xlvi, 650 pages</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. Goes beyond the standard engineering issues covered by most books and delves into structure-function relationshipsIntegration of knowledge across all areas of antibody engineering, development, and marketingDiscusses how current and future genetic engineering of cell lines will pave the way for much higher productivity</subfield></datafield><datafield tag="610" ind1="2" ind2="7"><subfield code="a">Antikörper</subfield><subfield code="0">(DE-588)10319455-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibodies, Monoclonal / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibodies, Monoclonal / diagnostic use</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotechnology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Monoclonal antibodies / Therapeutic use</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monoclonal antibodies</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotechnology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antikörper</subfield><subfield code="0">(DE-588)10319455-1</subfield><subfield code="D">b</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strohl, Lila M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/book/9781907568374</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-33-ESD</subfield><subfield code="a">ZDB-33-EBS</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029785523</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.sciencedirect.com/science/book/9781907568374</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-33-ESD</subfield><subfield code="q">FAW_PDA_ESD</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV044383302 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:51:25Z |
| institution | BVB |
| isbn | 1907568379 9781907568374 9781306189385 1306189381 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029785523 |
| oclc_num | 870891982 |
| open_access_boolean | |
| owner | DE-1046 |
| owner_facet | DE-1046 |
| physical | xlvi, 650 pages |
| psigel | ZDB-33-ESD ZDB-33-EBS ZDB-33-ESD FAW_PDA_ESD |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Woodhead Publishing |
| record_format | marc |
| spelling | Strohl, William R. Verfasser aut Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry William R. Strohl and Lila M. Strohl Cambridge, UK Woodhead Publishing © 2013 xlvi, 650 pages txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. Goes beyond the standard engineering issues covered by most books and delves into structure-function relationshipsIntegration of knowledge across all areas of antibody engineering, development, and marketingDiscusses how current and future genetic engineering of cell lines will pave the way for much higher productivity Antikörper (DE-588)10319455-1 gnd rswk-swf Antibodies, Monoclonal / therapeutic use Antibodies, Monoclonal / diagnostic use Immunotechnology fast Monoclonal antibodies / Therapeutic use fast Monoclonal antibodies Therapeutic use Immunotechnology Arzneimittel (DE-588)4003115-9 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Antikörper (DE-588)10319455-1 b Arzneimittel (DE-588)4003115-9 s 2\p DE-604 Strohl, Lila M. Sonstige oth http://www.sciencedirect.com/science/book/9781907568374 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Strohl, William R. Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry Antikörper (DE-588)10319455-1 gnd Antibodies, Monoclonal / therapeutic use Antibodies, Monoclonal / diagnostic use Immunotechnology fast Monoclonal antibodies / Therapeutic use fast Monoclonal antibodies Therapeutic use Immunotechnology Arzneimittel (DE-588)4003115-9 gnd |
| subject_GND | (DE-588)10319455-1 (DE-588)4003115-9 (DE-588)4143413-4 |
| title | Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry |
| title_auth | Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry |
| title_exact_search | Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry |
| title_full | Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry William R. Strohl and Lila M. Strohl |
| title_fullStr | Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry William R. Strohl and Lila M. Strohl |
| title_full_unstemmed | Therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry William R. Strohl and Lila M. Strohl |
| title_short | Therapeutic antibody engineering |
| title_sort | therapeutic antibody engineering current and future advances driving the strongest growth area in the pharmaceutical industry |
| title_sub | current and future advances driving the strongest growth area in the pharmaceutical industry |
| topic | Antikörper (DE-588)10319455-1 gnd Antibodies, Monoclonal / therapeutic use Antibodies, Monoclonal / diagnostic use Immunotechnology fast Monoclonal antibodies / Therapeutic use fast Monoclonal antibodies Therapeutic use Immunotechnology Arzneimittel (DE-588)4003115-9 gnd |
| topic_facet | Antikörper Antibodies, Monoclonal / therapeutic use Antibodies, Monoclonal / diagnostic use Immunotechnology Monoclonal antibodies / Therapeutic use Monoclonal antibodies Therapeutic use Arzneimittel Aufsatzsammlung |
| url | http://www.sciencedirect.com/science/book/9781907568374 |
| work_keys_str_mv | AT strohlwilliamr therapeuticantibodyengineeringcurrentandfutureadvancesdrivingthestrongestgrowthareainthepharmaceuticalindustry AT strohllilam therapeuticantibodyengineeringcurrentandfutureadvancesdrivingthestrongestgrowthareainthepharmaceuticalindustry |